newsfilter
← Latest News
GlobeNewswire·

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

  • Arbutus Biopharma Corporation announced plans for a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares.
  • The offer will accept share prices ranging from US$5.00 to US$5.75 per share, paid in cash.
  • The tender offer is expected to commence on or about August 24, 2026, & expire on or about September 29, 2026.
  • Funding for the offer will come from the company's existing cash on hand.
  • The company cited proceeds from a March 2026 settlement with Moderna as a key driver for returning financial value to shareholders.
  • Arbutus intends to continue enforcing its intellectual property rights against alleged infringers, including Pfizer & BioNTech, alongside licensee Genevant Sciences.
  • J.P. Morgan Securities LLC is designated as the Dealer-Manager, while Georgeson LLC & TSX Trust Company will serve as Information Agent & Depositary, respectively.
  • The offer is subject to obtaining exemptive relief under applicable securities laws in the United States & Canada.
  • Arbutus develops imdusiran (AB-729) & an oral PD-L1 inhibitor (AB-101) for chronic Hepatitis B infection.
  • Shareholders are urged to review the official tender offer statement once available via the SEC, SEDAR+, & the company's investor website.